Nothing Special   »   [go: up one dir, main page]

NO20020554L - Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav - Google Patents

Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav

Info

Publication number
NO20020554L
NO20020554L NO20020554A NO20020554A NO20020554L NO 20020554 L NO20020554 L NO 20020554L NO 20020554 A NO20020554 A NO 20020554A NO 20020554 A NO20020554 A NO 20020554A NO 20020554 L NO20020554 L NO 20020554L
Authority
NO
Norway
Prior art keywords
specificity
necrosis factor
tumor necrosis
antibody molecules
human tumor
Prior art date
Application number
NO20020554A
Other languages
English (en)
Other versions
NO20020554D0 (no
NO334808B1 (no
Inventor
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Andrew George Popplewell
Andrew Paul Chapman
David John King
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020554(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of NO20020554D0 publication Critical patent/NO20020554D0/no
Publication of NO20020554L publication Critical patent/NO20020554L/no
Publication of NO334808B1 publication Critical patent/NO334808B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
NO20020554A 2000-06-06 2002-02-04 CDR-podet antistoffmolekyl med spesifisitet for human TNF-alfa, forbindelse inneholdende antistoffmolekylet, DNA, klonings- eller ekspresjonsvektor, E.coli ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet, terapeutisk eller diagnostisk preparat, samt anvendelse av antistoffmolekylet NO334808B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (3)

Publication Number Publication Date
NO20020554D0 NO20020554D0 (no) 2002-02-04
NO20020554L true NO20020554L (no) 2002-04-08
NO334808B1 NO334808B1 (no) 2014-06-02

Family

ID=9893121

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20020554A NO334808B1 (no) 2000-06-06 2002-02-04 CDR-podet antistoffmolekyl med spesifisitet for human TNF-alfa, forbindelse inneholdende antistoffmolekylet, DNA, klonings- eller ekspresjonsvektor, E.coli ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet, terapeutisk eller diagnostisk preparat, samt anvendelse av antistoffmolekylet
NO20131316A NO339282B1 (no) 2000-06-06 2013-10-01 Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
NO2014026C NO2014026I2 (no) 2000-06-06 2014-10-23 Certolizumab pegol
NO20160694A NO341218B1 (no) 2000-06-06 2016-04-26 Antistoffmolekyl med spesifisitet for human tumornekrosefaktor-alfa, DNA, klonings- og ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet samt terapeutisk preparat

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20131316A NO339282B1 (no) 2000-06-06 2013-10-01 Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
NO2014026C NO2014026I2 (no) 2000-06-06 2014-10-23 Certolizumab pegol
NO20160694A NO341218B1 (no) 2000-06-06 2016-04-26 Antistoffmolekyl med spesifisitet for human tumornekrosefaktor-alfa, DNA, klonings- og ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet samt terapeutisk preparat

Country Status (42)

Country Link
US (4) US7012135B2 (no)
EP (4) EP1287140B1 (no)
JP (3) JP4064812B2 (no)
KR (1) KR20020047097A (no)
CN (1) CN1289671C (no)
AP (1) AP2092A (no)
AR (1) AR033978A1 (no)
AT (1) ATE451460T1 (no)
AU (1) AU783756B2 (no)
BE (1) BE2010C019I2 (no)
BG (1) BG66072B1 (no)
BR (2) BR0106682A (no)
CA (2) CA2707766C (no)
CY (6) CY1109889T1 (no)
CZ (1) CZ300737B6 (no)
DE (3) DE122010000027I1 (no)
DK (4) DK2230308T3 (no)
EC (1) ECSP024210A (no)
ES (5) ES2230975B2 (no)
FR (1) FR10C0015I2 (no)
GB (2) GB0013810D0 (no)
HU (4) HU230561B1 (no)
IL (3) IL147992A0 (no)
IS (2) IS2808B (no)
LT (1) LT2308975T (no)
LU (1) LU91674I2 (no)
MX (1) MXPA01013440A (no)
MY (1) MY136603A (no)
NL (1) NL300982I9 (no)
NO (4) NO334808B1 (no)
NZ (1) NZ516596A (no)
OA (1) OA12282A (no)
PE (1) PE20020292A1 (no)
PL (2) PL218516B1 (no)
PT (4) PT3059314T (no)
RU (1) RU2303604C2 (no)
SI (3) SI2230308T1 (no)
SK (1) SK288343B6 (no)
TR (1) TR201900227T4 (no)
TW (2) TWI353358B (no)
WO (1) WO2001094585A1 (no)
ZA (1) ZA200200097B (no)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2003225900A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Antibody disulfide isomers, use thereof, and methods of analyzing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BRPI0309868B8 (pt) 2002-05-02 2021-05-25 Wyeth Corp métodos de preparação de uma composição de reduzida fração conjugada inferior
ES2370710T3 (es) 2002-05-28 2011-12-22 Ucb Pharma, S.A. ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2942359A1 (en) * 2002-07-19 2015-11-11 AbbVie Biotechnology Ltd Treatment of TNF alpha related disorders
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003277828B2 (en) 2002-10-29 2009-06-04 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
ES2281822T3 (es) * 2003-08-13 2007-10-01 Sandoz Ag Vectores de expresion, celulas huesped transformadas y procedimiento de fermentacion para la produccion de polipeptidos recombinantes.
US20060173167A1 (en) * 2003-08-13 2006-08-03 Gunter Stempfer Process for the purification of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
ATE499385T1 (de) * 2004-12-29 2011-03-15 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
CA2609999C (en) 2005-06-07 2017-05-30 Esbatech Ag Stable and soluble antibodies inhibiting tnf.alpha.
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CA2648582C (en) * 2006-04-07 2016-12-06 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
RU2503463C2 (ru) 2006-07-03 2014-01-10 Чарльз Дэвид ЭДЕЙР Композиция для модулирования экспрессии молекул клеточной адгезии
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101652128B (zh) * 2007-03-02 2012-12-19 法纳姆公司 使用蜡状材料的缓释组合物
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
JP2011510667A (ja) * 2008-02-05 2011-04-07 デレネックス セラピューティクス アーゲー 軟骨変性に対する抗原結合性ポリペプチド
KR101687032B1 (ko) * 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
LT3722310T (lt) 2008-06-25 2024-12-27 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
HUE056007T2 (hu) 2008-06-25 2022-01-28 Novartis Ag Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
RU2567100C2 (ru) * 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
EP2451839B1 (en) 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
US9109216B2 (en) 2009-09-24 2015-08-18 Ucb Pharma, S.A. Bacterial host strain
BR112012007523A2 (pt) 2009-10-23 2017-06-20 Amgen British Columbia moléculas de anticorpo anti-gcc e composições e métodos relacionados
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
CA2791866A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
RU2766157C2 (ru) 2011-06-01 2022-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
EP2731973B1 (en) 2011-07-13 2017-11-15 UCB Biopharma SPRL Bacterial host strain expressing recombinant dsbc
EP2758513B1 (en) 2011-09-23 2018-05-16 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
WO2013041672A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016102378A1 (en) 2014-12-22 2016-06-30 Ucb Biopharma Sprl Method of protein manufacture
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
AU2017208153B2 (en) 2016-01-14 2021-01-28 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
DK3464318T3 (da) 2016-06-02 2021-06-28 Abbvie Inc Glucocorticoidreceptoragonist og immunkonjugater deraf
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN111417410B (zh) 2017-12-01 2023-06-23 艾伯维公司 糖皮质激素受体激动剂及其免疫缀合物
US20220127350A1 (en) 2019-01-31 2022-04-28 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
KR20240099199A (ko) 2021-09-24 2024-06-28 엑스브레인 바이오파마 에이비 재조합 단백질을 발현시키기 위한 dna 구조체 및 숙주 세포
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2108460T3 (es) * 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0871641A4 (en) 1995-04-20 2001-09-26 Kennedy Inst Of Rheumatology MULTIPLE ADMINISTRATION OF ANTI-TNF ANTIBODIES
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1015480A2 (en) * 1997-08-18 2000-07-05 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
BR0106682A (pt) 2002-05-14
US7012135B2 (en) 2006-03-14
US20080269465A1 (en) 2008-10-30
EP2308975A1 (en) 2011-04-13
DK1287140T3 (da) 2010-04-19
HU230669B1 (hu) 2017-07-28
NO20131316L (no) 2002-04-08
CN1383450A (zh) 2002-12-04
IS3016B (is) 2019-10-15
CY1114143T1 (el) 2016-07-27
CA2707766C (en) 2013-05-21
EP3059314B1 (en) 2018-10-24
BG66072B1 (bg) 2011-01-31
EP1287140B1 (en) 2009-12-09
PT3059314T (pt) 2019-02-01
CY1118220T1 (el) 2017-06-28
EP3059314A1 (en) 2016-08-24
JP2009171966A (ja) 2009-08-06
JP5185143B2 (ja) 2013-04-17
NO20160694A1 (no) 2002-04-08
IL195085A0 (en) 2009-08-03
DE122010000027I1 (de) 2010-08-12
NO339282B1 (no) 2016-11-21
PL353960A1 (en) 2003-12-15
HU230561B1 (hu) 2016-12-28
HK1051385A1 (en) 2003-08-01
PE20020292A1 (es) 2002-05-08
EP2308975B1 (en) 2016-08-10
SK3152002A3 (en) 2002-07-02
SI1287140T1 (sl) 2010-04-30
BE2010C019I2 (no) 2020-08-20
DE10192353T1 (de) 2003-05-22
IL147992A (en) 2009-06-15
EP1287140A1 (en) 2003-03-05
LT2308975T (lt) 2016-11-10
CY2019018I1 (el) 2020-05-29
MXPA01013440A (es) 2003-09-04
US20020151682A1 (en) 2002-10-17
CZ2002837A3 (cs) 2002-05-15
RU2303604C2 (ru) 2007-07-27
LU91674I2 (fr) 2010-05-31
LU91674I9 (no) 2019-01-03
HU230553B1 (hu) 2016-11-28
CN1289671C (zh) 2006-12-13
AP2002002690A0 (en) 2002-12-31
ATE451460T1 (de) 2009-12-15
MY136603A (en) 2008-10-31
OA12282A (en) 2006-05-11
JP2007105043A (ja) 2007-04-26
GB2366800B (en) 2005-01-19
BRPI0106682B1 (pt) 2020-10-13
NL300982I9 (nl) 2019-05-06
ES2230975B2 (es) 2007-04-16
CY2010011I1 (el) 2012-01-25
KR20020047097A (ko) 2002-06-21
TWI316088B (en) 2009-10-21
HUP0202346A3 (en) 2004-11-29
AU6051101A (en) 2001-12-17
ES2403217T3 (es) 2013-05-16
DE60140738D1 (de) 2010-01-21
TWI353358B (en) 2011-12-01
GB0013810D0 (en) 2000-07-26
WO2001094585A1 (en) 2001-12-13
BG106278A (bg) 2002-12-29
ES2600080T3 (es) 2017-02-07
EP2230308A1 (en) 2010-09-22
NZ516596A (en) 2004-07-30
US20060233800A1 (en) 2006-10-19
DK3059314T3 (en) 2019-02-18
FR10C0015I1 (no) 2010-04-16
FR10C0015I2 (fr) 2011-12-30
DK2308975T3 (da) 2016-10-31
GB0128386D0 (en) 2002-01-16
PL212738B1 (pl) 2012-11-30
US7186820B2 (en) 2007-03-06
IL147992A0 (en) 2002-09-12
ES2337763T3 (es) 2010-04-29
CY2019018I2 (el) 2020-05-29
NO341218B1 (no) 2017-09-11
HUP1600483A2 (no) 2002-10-28
HUS1700013I1 (hu) 2017-08-28
CZ300737B6 (cs) 2009-07-29
DK2230308T3 (da) 2013-05-06
US20030026805A1 (en) 2003-02-06
ZA200200097B (en) 2003-01-06
IS6217A (is) 2002-01-03
ECSP024210A (es) 2002-05-23
TW200817430A (en) 2008-04-16
AU783756B2 (en) 2005-12-01
NO20020554D0 (no) 2002-02-04
NL300982I1 (no) 2019-05-01
AP2092A (en) 2010-02-28
CA2707766A1 (en) 2001-12-13
NO2014026I2 (no) 2018-02-14
HUP1600016A2 (en) 2002-10-28
IS2808B (is) 2012-09-15
ES2707714T3 (es) 2019-04-04
ES2230975A1 (es) 2005-05-01
CA2380298A1 (en) 2001-12-13
HUP0202346A2 (en) 2002-10-28
SI2230308T1 (sl) 2013-06-28
JP2003535591A (ja) 2003-12-02
PL218516B1 (pl) 2014-12-31
BRPI0106682B8 (pt) 2021-05-25
CY1109889T1 (el) 2012-01-25
PT2230308E (pt) 2013-05-03
TR201900227T4 (tr) 2019-02-21
PL399351A1 (pl) 2012-12-17
JP4064812B2 (ja) 2008-03-19
GB2366800A (en) 2002-03-20
NO334808B1 (no) 2014-06-02
EP2230308B1 (en) 2013-01-23
US7402662B2 (en) 2008-07-22
SK288343B6 (sk) 2016-04-01
SI2308975T1 (sl) 2016-11-30
US7977464B2 (en) 2011-07-12
NO2014026I1 (no) 2014-10-23
PT2308975T (pt) 2016-11-14
PT1287140E (pt) 2010-03-08
CY1121173T1 (el) 2020-05-29
JP4476989B2 (ja) 2010-06-09
HK1148776A1 (en) 2011-09-16
AR033978A1 (es) 2004-01-21
CA2380298C (en) 2010-09-28
CY2010011I2 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
NO20020554L (no) Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
IS6965A (is) Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
DK1537140T3 (da) Nukleinsyre og tilsvarende protein betegnet 161P2F10B, der er anvendelige i behandling og detektering af cancer
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
SE0202257D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XVII
SE0202260D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XX
SE0202255D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XV
SE0201953D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy II
NO20014300L (no) Nytt protein og dets anvendelse
SE0201957D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy VII
SE0201867D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy I
SE0201956D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy VI

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: CIMZIA - CERTOLIZUMAB PEGOL; REG. NO/DATE: EU/1/09/544/001-002 20091001

Spc suppl protection certif: 2014026

Filing date: 20141023

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: CERTOLIZUMAB PEGOL; REG. NO/DATE: EU/1/09/544/001-002 20091001

Spc suppl protection certif: 2014026

Filing date: 20141023

Extension date: 20241006

MK1K Patent expired